Angle PLC 2023 AR2
The report outlines ANGLE plc's commercial and operational progress for the fiscal year 2023, highlighting a doubling of revenues to £2.2 million driven by product sales of the Parsortix system and pharma services contracts. Key achievements include the launch of multiple downstream assays, a strategic partnership with BioView, and the introduction of the Portrait+ CTC Staining Kit. The company also advanced its clinical studies, including the INFORM study, and developed a dual analysis solution for comprehensive DNA molecular analysis of CTCs and ctDNA. Despite challenging economic conditions, ANGLE streamlined operations by centralizing laboratory services in the UK to extend its cash runway.
Company: Angle PLC
Sector: Professional & technical services
Country: United Kingdom
Year: 2023
Type: AR2
Pages: 134
Back to company
Angle PLC
Annual Report And Financial Statements
The report outlines ANGLE plc's commercial and operational progress for the fiscal year 2023, highlighting a doubling of revenues to £2.2 million driven by product sales of the Parsortix system and pharma services contracts. Key achievements include the launch of multiple downstream assays, a strategic partnership with BioView, and the introduction of the Portrait+ CTC Staining Kit. The company also advanced its clinical studies, including the INFORM study, and developed a dual analysis solution for comprehensive DNA molecular analysis of CTCs and ctDNA. Despite challenging economic conditions, ANGLE streamlined operations by centralizing laboratory services in the UK to extend its cash runway.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2023
Reporting Period
Jan 1, 2023 - Dec 31, 2023
Fiscal Year
2023
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Renewable Energy
Employees